Earnings report 📈 Stocks 🌍 United States

ALX Oncology Reports Q3 2026 Net Loss of $21,826 Thousand

ALX Oncology posted a Q3 2026 net loss of $21,826 thousand while detailing upcoming clinical catalysts, including ALX2004 data in December 2026 and ASPEN-09-Breast results in 2H 2027.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: ALXO → 3/10 (55% confidence).

📊 Affected Assets (1)

ALXO
Neutral 🤖 55%
📅 Short-term 🌍 US · Explicit

Q3 net loss of $21,826 thousand was roughly flat versus $22,144 thousand a year earlier, and quarterly R&D spending of $17,463 thousand was in line, so the results themselves are unremarkable. The weighted-average share count of 140,904,752 versus 53,577,066 a year ago signals substantial dilution, while cash of $147,206 thousand gives a long runway. The real price drivers are the promised catalysts: ALX2004 Phase 1 safety and early efficacy data in December 2026 and ASPEN-09-Breast topline data in 2H 2027.

Catalysts
  • • ALX2004 Phase 1 dose-escalation safety and early efficacy data plus KOL webinar in December 2026
  • • Topline data from approximately 120 patients in the Phase 2 ASPEN-09-Breast trial expected in 2H 2027
Risk Factors
  • • Weighted-average shares grew to 140,904,752 from 53,577,066, pointing to heavy dilution
  • • Cash of $147,206 thousand will be consumed by ongoing trials with no revenue yet

🧭 Full analysis of these assets

🎯 Key Takeaways

  • Reported a Q3 2026 net loss of $21,826 thousand, compared to $22,144 thousand in Q3 2025.
  • Research and development expenses for the quarter were $17,463 thousand, nearly flat against $17,441 thousand in the prior year.
  • Weighted-average shares outstanding increased to 140,904,752 from 53,577,066 in the year-ago period.
  • Company expects to release Phase 1 safety and early efficacy data for ALX2004 in December 2026.
  • Topline data from approximately 120 patients in the Phase 2 ASPEN-09-Breast trial is anticipated in 2H 2027.

📝 Executive Summary

ALX Oncology Holdings reported a third-quarter 2026 net loss of $21,826 thousand, consistent with the $22,144 thousand loss recorded in the same period last year. The company maintains a cash position of $147,206 thousand as it advances its clinical pipeline, including the ALX2004 and ASPEN-09-Breast programs.

❓ FAQ

Did ALX Oncology beat or miss in the third quarter of 2026?

There is no revenue to compare; the quarterly net loss of $21,826 thousand was slightly better than the $22,144 thousand loss a year earlier, with R&D costs essentially unchanged, so the financial results were roughly in line.

What could move the stock after this report?

The stated upcoming catalysts are the first safety and early efficacy data for ALX2004 in EGFR-expressing tumors, expected with a webinar in December 2026, and topline results from about 120 patients in the ASPEN-09-Breast breast cancer trial in the second half of 2027.